AstraZeneca Annual Report and Operational Review Form 20-F Information 2004 25 Sales growth is shown in both reported and underlying performance.
Reported performance takes into account all the factors including those which we cannot influence, principally currency exchange rates that have affected the results of our business.
Underlying performance shows sales growth at constant exchange rates CER to reflect the volume and price changes of the geographic and therapy areas and individual products by excluding the effects of exchange.
A description of the calculation of this measure is set out in the Financial Review on page 38, together with the reasons for its use.
Infection We aim to build a franchise in the treatment of infectious diseases by increasing sales of Merrem and by exploiting our traditional, structural and genomic-based Discovery technologies to bring new products to market.
Key product performance 2004 2003 2002 2004 compared to 2003 2003 compared to 2002 Growth Growth due to due to Growth exchange Growth exchange Growth Growth Growth Growth Sales underlying effects Sales underlying effects Sales underlying reported underlying reported $m $m $m $m $m $m $m %% %% Merrem 423 53 24 346 46 15 285 15 22 16 21 Other 116 20 6130 36 11155 16 11 24 17 Total 539 33 30 476 10 26 440 713 28 Products The performance of the therapy area was Therapy area overview Merrem Meronem meropenem is an driven by Merrem sales, particularly in intravenous carbapenem antibiotic for the Europe with growth of 14% to $221 million.
Infection world market value: treatment of serious, hospital-acquired $53 billion.
A Supplementary New Drug Performance 2003 Application was filed in the US in July 2004 Reported performance Infectious diseases cause more than aimed at securing an indication for skin and Sales grew by 8% on a reported basis, 11 million deaths each year.
skin structure infections in 2005. rising from $440 million to $476 million.
World demand for antibiotics remains Pipeline Underlying performance high due to escalating resistance and Our R&D facility in Boston, US is Sales of Merrem grew steadily by a further the increased risk of serious infections.
progressing a range of projects using 16% for the year to $346 million.
Growth traditional, structural and genomic-based was largely attributable to sales outside 2004 in brief technologies to deliver innovative antithe US, which were up 19% to $283 million.
bacterial agents to the infection pipeline.
In the US, sales grew by 7% to $63 million.
Steady underlying growth for Merrem in the US 8%, Europe 14% and Work continues at our new R&D facility globally 15%.
opened in Bangalore, India which is dedicated to finding a new treatment Supplementary New Drug Application for tuberculosis.
Tuberculosis remains a filed in the US for treating skin and worldwide threat and is newly diagnosed skin structure infections.
in approximately two million people every year in India and over eight million people worldwide.
Performance 2004 Reported performance Infection sales growth was 13% as revenues rose by $63 million to $539 million.
Underlying performance Excluding exchange effects of $30 million, underlying sales in Infection increased by $33 million, 7%.
